Pacheco Tatiana, Bustos Rosa-Helena, González Diana, Garzón Vivian, García Julio-Cesar, Ramírez Daniela
Evidence-Based Therapeutic Group, Clinical Pharmacology, Universidad de la Sabana, Chía 140013, Colombia.
Facultad de Medicina, Univesidad de La Sabana, Chía 140013, Colombia.
Antibiotics (Basel). 2019 Jul 24;8(3):100. doi: 10.3390/antibiotics8030100.
Antimicrobial resistance to antibiotic treatment has significantly increased during recent years, causing this to become a worldwide public health problem. More than 70% of pathogenic bacteria are resistant to at least one of the currently used antibiotics. Polymyxin E (colistin) has recently been used as a "last line" therapy when treating Gram-negative multi-resistant bacteria. However, little is known about these molecules' pharmacological use as they have been discontinued because of their high toxicity. Recent research has been focused on determining colistimethate sodium's pharmacokinetic parameters to find the optimal dose for maintaining a suitable benefit-risk balance. This review has thus been aimed at describing the use of colistin on patients infected by multi-drug resistant bacteria and the importance of measuring this drug's plasma levels in such patients.
近年来，对抗生素治疗的抗菌耐药性显著增加，使其成为一个全球性的公共卫生问题。超过70%的病原菌对至少一种目前使用的抗生素具有耐药性。多粘菌素E（黏菌素）最近已被用作治疗革兰氏阴性多重耐药菌的“最后一线”疗法。然而，由于其高毒性已被停用，人们对这些分子的药理学用途知之甚少。最近的研究集中在确定多粘菌素甲磺酸钠的药代动力学参数，以找到维持合适的效益-风险平衡的最佳剂量。因此，本综述旨在描述黏菌素在多重耐药菌感染患者中的应用以及在此类患者中测量该药物血浆水平的重要性。
